Header Logo

Connection

Allison Naleway to Aged

Back to Details
This is a "connection" page, showing publications Allison Naleway has written about Aged.
Allison Naleway
Connection Strength
1.135
Aged
  1. Differences in influenza vaccination coverage by race and ethnicity across age groups in the Vaccine Safety Datalink, 2017-18 through 2022-23 influenza seasons. Vaccine. 2025 Oct 03; 64:127667.
    View in: PubMed
    Score: 0.108
  2. Parental intent to vaccinate children with the updated 2023-2024 COVID-19 vaccine. Vaccine. 2025 Sep 17; 63:127618.
    View in: PubMed
    Score: 0.108
  3. Incidence of SARS-CoV-2 Infection, Emergency Department Visits, and Hospitalizations Because of COVID-19 Among Persons Aged =12 Years, by COVID-19 Vaccination Status - Oregon and Washington, July 4-September 25, 2021. MMWR Morb Mortal Wkly Rep. 2021 Nov 19; 70(46):1608-1612.
    View in: PubMed
    Score: 0.083
  4. Barriers and facilitators to influenza vaccination and vaccine coverage in a cohort of health care personnel. Am J Infect Control. 2014 Apr; 42(4):371-5.
    View in: PubMed
    Score: 0.049
  5. Frequency of medically attended events following rapid revaccination with trivalent inactivated influenza vaccine. Vaccine. 2010 Nov 16; 28(49):7713-5.
    View in: PubMed
    Score: 0.038
  6. Gender differences in asthma management and quality of life. J Asthma. 2006 Sep; 43(7):549-52.
    View in: PubMed
    Score: 0.029
  7. Household Transmission of SARS-CoV-2 in Washington and Oregon, United States, 2022-2024. J Pediatric Infect Dis Soc. 2026 Aug 04; 15(8).
    View in: PubMed
    Score: 0.029
  8. Estimated Effectiveness of 2024-2025 COVID-19 Vaccines in Adults. JAMA Intern Med. 2026 08 01; 186(8):976-986.
    View in: PubMed
    Score: 0.029
  9. Influenza Activity and Estimated Vaccine Effectiveness During the 2025-2026 Influenza Season. JAMA Netw Open. 2026 Jun 01; 9(6):e2618581.
    View in: PubMed
    Score: 0.028
  10. Interim Estimated Effectiveness of 2025-2026 COVID-19 Vaccines in Adults Using a Test-Negative Design. JAMA Netw Open. 2026 Jun 01; 9(6):e2625152.
    View in: PubMed
    Score: 0.028
  11. Influenza household transmission and genomic diversity in the United States: A prospective cohort study, 2022-2024. J Infect. 2026 May; 92(5):106748.
    View in: PubMed
    Score: 0.028
  12. Estimated Burden of COVID-19 Illnesses, Medical Visits, Hospitalizations, and Deaths in the US From October 2022 to September 2024. JAMA Intern Med. 2026 03 01; 186(3):321-330.
    View in: PubMed
    Score: 0.028
  13. Estimated 2023-2024 COVID-19 Vaccine Effectiveness in Adults. JAMA Netw Open. 2025 06 02; 8(6):e2517402.
    View in: PubMed
    Score: 0.027
  14. Interim Estimates of 2024-2025 COVID-19 Vaccine Effectiveness Among Adults Aged =18 Years - VISION and IVY Networks, September 2024-January 2025. MMWR Morb Mortal Wkly Rep. 2025 Feb 27; 74(6):73-82.
    View in: PubMed
    Score: 0.026
  15. Epidemiology of systemic lupus erythematosus in rural Wisconsin. Lupus. 2005; 14(10):862-6.
    View in: PubMed
    Score: 0.026
  16. Respiratory syncytial virus (RSV) vaccine effectiveness against RSV-associated hospitalisations and emergency department encounters among adults aged 60 years and older in the USA, October, 2023, to March, 2024: a test-negative design analysis. Lancet. 2024 Oct 19; 404(10462):1547-1559.
    View in: PubMed
    Score: 0.025
  17. Disparities in COVID-19 vaccination receipt by race, ethnicity, and social determinants of health among a large patient population in a network of community-based healthcare centers. Vaccine. 2024 Oct 24; 42(24):126288.
    View in: PubMed
    Score: 0.025
  18. Influenza Vaccine Effectiveness Against Influenza A-Associated Emergency Department, Urgent Care, and Hospitalization Encounters Among US Adults, 2022-2023. J Infect Dis. 2024 Jul 25; 230(1):141-151.
    View in: PubMed
    Score: 0.025
  19. Estimation of COVID-19 mRNA Vaccine Effectiveness and COVID-19 Illness and Severity by Vaccination Status During Omicron BA.4 and BA.5 Sublineage Periods. JAMA Netw Open. 2023 03 01; 6(3):e232598.
    View in: PubMed
    Score: 0.023
  20. Active Postlicensure Safety Surveillance for Recombinant Zoster Vaccine Using Electronic Health Record Data. Am J Epidemiol. 2023 Feb 01; 192(2):205-216.
    View in: PubMed
    Score: 0.023
  21. Lyme disease incidence in Wisconsin: a comparison of state-reported rates and rates from a population-based cohort. Am J Epidemiol. 2002 Jun 15; 155(12):1120-7.
    View in: PubMed
    Score: 0.022
  22. Waning 2-Dose and 3-Dose Effectiveness of mRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance - VISION Network, 10 States, August 2021-January 2022. MMWR Morb Mortal Wkly Rep. 2022 Feb 18; 71(7):255-263.
    View in: PubMed
    Score: 0.021
  23. Laboratory-Confirmed COVID-19 Among Adults Hospitalized with COVID-19-Like Illness with Infection-Induced or mRNA Vaccine-Induced SARS-CoV-2 Immunity - Nine States, January-September 2021. MMWR Morb Mortal Wkly Rep. 2021 Nov 05; 70(44):1539-1544.
    View in: PubMed
    Score: 0.021
  24. Effectiveness of 2-Dose Vaccination with mRNA COVID-19 Vaccines Against COVID-19-Associated Hospitalizations Among Immunocompromised Adults - Nine States, January-September 2021. MMWR Morb Mortal Wkly Rep. 2021 Nov 05; 70(44):1553-1559.
    View in: PubMed
    Score: 0.021
  25. Interim Estimates of COVID-19 Vaccine Effectiveness Against COVID-19-Associated Emergency Department or Urgent Care Clinic Encounters and Hospitalizations Among Adults During SARS-CoV-2 B.1.617.2 (Delta) Variant Predominance - Nine States, June-August 2021. MMWR Morb Mortal Wkly Rep. 2021 09 17; 70(37):1291-1293.
    View in: PubMed
    Score: 0.021
  26. COVID-19 Vaccination Coverage Among Insured Persons Aged =16 Years, by Race/Ethnicity and Other Selected Characteristics - Eight Integrated Health Care Organizations, United States, December 14, 2020-May 15, 2021. MMWR Morb Mortal Wkly Rep. 2021 Jul 16; 70(28):985-990.
    View in: PubMed
    Score: 0.020
  27. Vaccine safety in HIV-infected adults within the Vaccine Safety Datalink Project. Vaccine. 2019 05 31; 37(25):3296-3302.
    View in: PubMed
    Score: 0.017
  28. A model for rapid, active surveillance for medically-attended acute gastroenteritis within an integrated health care delivery system. PLoS One. 2018; 13(8):e0201805.
    View in: PubMed
    Score: 0.017
  29. Rates and risk factors associated with hospitalization for pneumonia with ICU admission among adults. BMC Pulm Med. 2017 Dec 16; 17(1):208.
    View in: PubMed
    Score: 0.016
  30. Risk of venous thromboembolism following influenza vaccination in adults aged 50years and older in the Vaccine Safety Datalink. Vaccine. 2017 10 13; 35(43):5872-5877.
    View in: PubMed
    Score: 0.016
  31. Demographic characteristics of members of the Vaccine Safety Datalink (VSD): A comparison with the United States population. Vaccine. 2015 Aug 26; 33(36):4446-50.
    View in: PubMed
    Score: 0.013
  32. Risk of Herpes Zoster and Disseminated Varicella Zoster in Patients Taking Immunosuppressant Drugs at the Time of Zoster Vaccination. Mayo Clin Proc. 2015 Jul; 90(7):865-73.
    View in: PubMed
    Score: 0.013
  33. Antibody response to influenza A(H1N1)pdm09 among healthcare personnel receiving trivalent inactivated vaccine: effect of prior monovalent inactivated vaccine. J Infect Dis. 2014 Jun 01; 209(11):1705-14.
    View in: PubMed
    Score: 0.012
  34. Safety of the yellow Fever vaccine: a retrospective study. J Travel Med. 2013 Nov-Dec; 20(6):368-73.
    View in: PubMed
    Score: 0.012
  35. Further evidence for bias in observational studies of influenza vaccine effectiveness: the 2009 influenza A(H1N1) pandemic. Am J Epidemiol. 2013 Oct 15; 178(8):1327-36.
    View in: PubMed
    Score: 0.012
  36. Mortality rates and cause-of-death patterns in a vaccinated population. Am J Prev Med. 2013 Jul; 45(1):91-97.
    View in: PubMed
    Score: 0.012
  37. Secular trends in diagnostic code density in electronic healthcare data from health care systems in the Vaccine Safety Datalink project. Vaccine. 2013 Feb 04; 31(7):1080-5.
    View in: PubMed
    Score: 0.011
  38. Safety of a tetanus-diphtheria-acellular pertussis vaccine when used off-label in an elderly population. Clin Infect Dis. 2013 Feb; 56(3):315-21.
    View in: PubMed
    Score: 0.011
  39. Patterns in influenza antiviral medication use before and during the 2009 H1N1 pandemic, Vaccine Safety Datalink Project, 2000-2010. Influenza Other Respir Viruses. 2012 Nov; 6(6):e143-51.
    View in: PubMed
    Score: 0.011
  40. The expected emotional benefits of influenza vaccination strongly affect pre-season intentions and subsequent vaccination among healthcare personnel. Vaccine. 2012 May 21; 30(24):3557-65.
    View in: PubMed
    Score: 0.011
  41. H1N1 and seasonal influenza vaccine safety in the vaccine safety datalink project. Am J Prev Med. 2011 Aug; 41(2):121-8.
    View in: PubMed
    Score: 0.010
  42. Monitoring vaccine safety using the Vaccine Safety Datalink: utilizing immunization registries for pandemic influenza. Vaccine. 2011 Jul 12; 29(31):4891-6.
    View in: PubMed
    Score: 0.010
  43. Patterns of pneumococcal vaccination and revaccination in elderly and non-elderly adults: a Vaccine Safety Datalink study. BMC Infect Dis. 2009 Mar 25; 9:37.
    View in: PubMed
    Score: 0.009
  44. Validation of a screening instrument to identify persons for exclusion from smallpox vaccination. Clin Infect Dis. 2005 Feb 15; 40(4):620-3.
    View in: PubMed
    Score: 0.006
  45. Incidence of myocardial infarction in a general population: the Marshfield Epidemiologic Study Area. WMJ. 2002; 101(7):46-52.
    View in: PubMed
    Score: 0.005

© 2026 Kaiser Permanente

Your Privacy Choices